Latest Myocet Stories
DSMB's recommendation follows 1(rst) interim analysis QUÉBEC CITY, April 27, 2015 /PRNewswire/ - Aeterna Zentaris Inc.
Median progression-free survival of 7.6 months reported for overall study population whose disease has progressed on a median of 4 prior therapies CAMBRIDGE, Mass., April 20, 2015 /PRNewswire/
LAGUNA HILLS, Calif., Feb.
QUEBEC CITY, June 2, 2014 /PRNewswire/ - Aeterna Zentaris Inc.
LAGUNA HILLS, Calif., April 17, 2014 /PRNewswire/ -- NanoSmart(®) and NanoValent, private pharmaceutical companies developing novel cancer pharmaceuticals, have entered into a research collaboration
A remarkable 98.7 percent of certain lower-risk breast cancer patients were cancer free for at least three years after taking a combination of the drugs Herceptin and Taxol.
A recent FDA-approved combination of therapies used to target HER2-positive breast cancer does not lead to increased cardiac problems for patients, but doctors should regularly perform cardiac
- Stoppage; cessation (of labor).
- A standing still or idling (of mills, factories, etc.).